Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
about
M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B.Evaluation of mucoadhesive PLGA microparticles for nasal immunization.Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.Alginate-chitosan-PLGA composite microspheres enabling single-shot hepatitis B vaccination.The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.Implication of nanoparticles/microparticles in mucosal vaccine delivery.Innovative strategies for co-delivering antigens and CpG oligonucleotides.Peptide/protein vaccine delivery system based on PLGA particles.The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.Advances in effective vaccine development against hepatitis B: focus on mucosal vaccine delivery strategies.Non-aggregated protamine-coated poly(lactide-co-glycolide) nanoparticles of cisplatin crossed blood-brain barrier, enhanced drug delivery and improved therapeutic index in glioblastoma cells: in vitro studies."Prevention of structural perturbation and aggregation of hepatitis B surface antigen: screening of various additives".Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres.Development characterizations and evaluation of Poly(-ϵ-caprolactone)-based microspheres for hepatitis B surface antigen delivery
P2860
Q33307430-36E7A448-32C8-4CEE-A0AD-5C46341848FBQ33545402-40A90115-E68B-45AB-AAF0-31B7C216A10EQ33749489-DDF3E1CB-1299-453C-9856-807B8430E4B8Q33821392-1B6A4BD3-34E7-47CD-988C-7DC91CCABDA1Q34293716-C06DD0C6-B1BF-42FB-AC73-EFAF69DF5782Q36062758-CD8BAE12-41B1-475F-9FD7-97C536B69BA0Q36837152-071FA69A-B4F4-4BC1-B684-1A20C283A490Q37130626-39F0B0CA-7CE7-4EA0-9439-56F9B60EABC0Q37838652-E5134657-B41F-4A76-9902-A1BD67DF56A3Q37956385-C06433FB-2A73-4425-9B09-A2537CF8C6BDQ38027857-77943F54-0F2A-4CD4-BFFE-592D45EAD482Q38981407-5FE5BB39-AFF6-454D-B84D-186F014F9294Q44989827-46192552-111E-407A-8EF0-83E7A63BA38EQ45803020-8243F8B3-96DB-44DE-80F7-6DF038025101Q58865840-032F5AB8-0DD9-42BA-A977-34D301F8D3C5
P2860
Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Development of a single-dose s ...... d vaccine against hepatitis B.
@en
Development of a single-dose s ...... d vaccine against hepatitis B.
@nl
type
label
Development of a single-dose s ...... d vaccine against hepatitis B.
@en
Development of a single-dose s ...... d vaccine against hepatitis B.
@nl
prefLabel
Development of a single-dose s ...... d vaccine against hepatitis B.
@en
Development of a single-dose s ...... d vaccine against hepatitis B.
@nl
P2093
P2860
P356
P1476
Development of a single-dose s ...... d vaccine against hepatitis B.
@en
P2093
D Prabakaran
K S Jaganathan
Paramjit Singh
Suresh P Vyas
Vivek Mishra
P2860
P304
P356
10.1211/0022357044418
P577
2004-10-01T00:00:00Z